The Vector Everyone Needs
At this time over 1,000 gene therapy clinical trials are underway, and the global market cap is currently 2.6 billion dollars. It is expected to grow at a CAGR of 20.4% from 2021 to 2028.
While this forecast is encouraging, we believe it is very conservative. Gene therapy is finding, and will continue to find, new applications. Moreover, its uses are not confined to medicine. Complex problems, like the aging process, are modulated by a variety of factors. A larger vector is a necessity. From cosmetic enhancement to interstellar travel, gene therapy’s uses are virtually unlimited when delivered with a vector like BioViva’s CMV.
The best gene therapy is the one that works safely, predictably, and affordably. This hinges upon its delivery method, its vector. From the beginning BioViva has aimed to tackle the diseases of aging by targeting the aging process with gene therapy. To do this effectively we need to carry a lot of cargo. This is why we’ve developed our own vector. It does what others can’t.
One time-honored path to success is to offer a universally needed service. During the Gold Rush many more fortunes were made selling picks, pans, and rations to miners than were made by prospecting. Very few miners struck gold, but they all needed tools. BioViva’s CMV is the indispensable technology for the next generation of genetic therapeutics.